Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
May 21, 2024 16:05 ET
|
Erasca, Inc.
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
May 16, 2024 20:02 ET
|
Erasca, Inc.
Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce...
Erasca Announces Pricing of Underwritten Offering of Common Stock
May 16, 2024 20:00 ET
|
Erasca, Inc.
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Reports First Quarter 2024 Business Updates and Financial Results
May 08, 2024 16:01 ET
|
Erasca, Inc.
Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and...
Erasca to Present at the Bank of America Health Care Conference
May 07, 2024 08:00 ET
|
Erasca, Inc.
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
April 24, 2024 16:05 ET
|
Erasca, Inc.
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature...
Erasca Announces $45 Million Oversubscribed Private Placement Financing
March 27, 2024 20:30 ET
|
Erasca, Inc.
SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS) (“Erasca”), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing...
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
March 27, 2024 16:01 ET
|
Erasca, Inc.
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib...
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
February 14, 2024 08:00 ET
|
Erasca, Inc.
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data in RAS Q61X solid tumors expected...
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...